Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan post-marketing study of Peficitinib use in RA patients (switch from bDMARDs)
jRCT1031220112Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of peficitinib in rheumatoid arthritis (RA), sponsored by Astellas Pharma. Primary endpoint: Change in DAS28-ESR from index date to 24 weeks. Started Jul 2022; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT1031220112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220112.